MX2017005874A - Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf. - Google Patents

Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf.

Info

Publication number
MX2017005874A
MX2017005874A MX2017005874A MX2017005874A MX2017005874A MX 2017005874 A MX2017005874 A MX 2017005874A MX 2017005874 A MX2017005874 A MX 2017005874A MX 2017005874 A MX2017005874 A MX 2017005874A MX 2017005874 A MX2017005874 A MX 2017005874A
Authority
MX
Mexico
Prior art keywords
high concentration
protein solution
formulation containing
containing high
vegf antibody
Prior art date
Application number
MX2017005874A
Other languages
English (en)
Other versions
MX383808B (es
Inventor
Wang Li
Zhang Huixiang
Boring Charles
Zeng Yuhong
Alani Laman
Kulshreshtha Alok
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005874(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2017005874A publication Critical patent/MX2017005874A/es
Publication of MX383808B publication Critical patent/MX383808B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona anticuerpos anti-VEGF formulados como composiciones farmacéuticas acuosas de alta concentración, adecuadas para inyección, preferiblemente, una inyección intravitreal. Las composiciones farmacéuticas acuosas son útiles para la entrega de una alta concentración del ingrediente activo anticuerpo a un paciente sin niveles altos de agregación de anticuerpo y sin niveles altos de material particulado sub-visible. Una composición farmacéutica de la invención que comprende un anticuerpo que tiene una concentración de al menos 50mg/ml. Una composición farmacéutica acuosa de la invención que incluye un azúcar, un agente regulador de pH y un surfactante.
MX2017005874A 2014-11-07 2015-11-06 Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf. MX383808B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US201462088061P 2014-12-05 2014-12-05
PCT/US2015/059571 WO2016073915A1 (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody

Publications (2)

Publication Number Publication Date
MX2017005874A true MX2017005874A (es) 2017-06-26
MX383808B MX383808B (es) 2025-03-14

Family

ID=54697654

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017005874A MX383808B (es) 2014-11-07 2015-11-06 Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf.
MX2017005875A MX383399B (es) 2014-11-07 2015-11-06 Un antagonista anti-vegf para usarse en el tratamiento de enfermedades oculares.
MX2021006768A MX2021006768A (es) 2014-11-07 2017-05-04 Metodos para tratar enfermedades oculares.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2017005875A MX383399B (es) 2014-11-07 2015-11-06 Un antagonista anti-vegf para usarse en el tratamiento de enfermedades oculares.
MX2021006768A MX2021006768A (es) 2014-11-07 2017-05-04 Metodos para tratar enfermedades oculares.

Country Status (25)

Country Link
US (6) US10689438B2 (es)
EP (3) EP4684797A3 (es)
JP (6) JP6753848B2 (es)
KR (4) KR20170082526A (es)
CN (4) CN120938921A (es)
AU (6) AU2015342818B2 (es)
BR (2) BR112017008093A2 (es)
CA (1) CA2966646A1 (es)
CL (2) CL2017001115A1 (es)
CO (1) CO2017004596A2 (es)
EA (1) EA201790989A1 (es)
EC (1) ECSP17034829A (es)
ES (1) ES3051145T3 (es)
GT (1) GT201700096A (es)
IL (5) IL251642B (es)
MX (3) MX383808B (es)
MY (2) MY183807A (es)
NZ (1) NZ730821A (es)
PE (1) PE20170780A1 (es)
PH (3) PH12021550147A1 (es)
RU (1) RU2722643C2 (es)
SG (3) SG11201702954XA (es)
TN (1) TN2017000128A1 (es)
TW (4) TWI806150B (es)
WO (2) WO2016073918A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
KR20190049934A (ko) 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
MX2017009759A (es) 2015-01-28 2017-10-27 Pfizer Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
ES2894802T3 (es) 2015-09-23 2022-02-15 Aerpio Pharmaceuticals Inc Activadores de Tie-2 para su uso en el tratamiento de la presión intraocular
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
CA3077518C (en) * 2016-09-07 2021-10-19 Frederic Fellouse Synthetic antibodies against vegf and their uses
EP3518971A4 (en) * 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN109562166B (zh) * 2017-04-28 2021-04-02 苏州思坦维生物技术股份有限公司 一种眼用药物组合物及其用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
AU2018345807B2 (en) 2017-10-06 2025-02-06 Novo Nordisk A/S Methods of detecting transthyretin
CU24731B1 (es) 2017-10-06 2025-01-15 Prothena Biosciences Ltd Anticuerpos anti-transtiretina
PE20211453A1 (es) * 2017-11-29 2021-08-05 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
WO2019124946A1 (ko) 2017-12-22 2019-06-27 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
AU2019212622B2 (en) 2018-01-26 2024-05-23 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
SG11202006712XA (en) * 2018-02-06 2020-08-28 Hoffmann La Roche Treatment of ophthalmologic diseases
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
KR20200131839A (ko) * 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
WO2019180261A1 (en) * 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
CN112262158B (zh) * 2018-04-10 2024-08-09 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
SG11202103670XA (en) * 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
MY195550A (en) * 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
WO2020096695A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
PE20211602A1 (es) * 2018-12-18 2021-08-18 Novartis Ag Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
TW202532428A (zh) 2019-04-26 2025-08-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
IL296119A (en) * 2020-03-04 2022-11-01 Shanghai Henlius Biotech Inc Pharmaceutical formulation comprising bevacizumab
CN113698478B (zh) * 2020-05-21 2025-11-18 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其稳定制剂
KR20220001106A (ko) 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
TW202216761A (zh) 2020-07-16 2022-05-01 瑞士商諾華公司 抗β細胞素抗體、其片段及多特異性結合分子
KR20240008821A (ko) * 2021-05-17 2024-01-19 리제너론 파아마슈티컬스, 인크. 혈관신생성 눈 장애 치료를 위한 연장된 고용량 vegf 길항제 요법
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
TW202412840A (zh) * 2022-09-16 2024-04-01 大陸商齊魯製藥有限公司 一種穩定的高濃度自緩衝藥物組合物
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025231345A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for ocular diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2654510C (en) * 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
BRPI0914251B1 (pt) * 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
AU2009270405B2 (en) 2008-06-30 2014-06-05 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
BR112012013093A2 (pt) 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
KR20190049934A (ko) * 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
AR086823A1 (es) * 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
CA2850572A1 (en) * 2011-10-20 2013-04-25 Esbatech, A Novartis Company Llc Stable multiple antigen-binding antibody
CN111700879A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
DE202013000688U1 (de) 2012-07-03 2013-03-05 Novartis Ag Glas-Spritze
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN110538322A (zh) 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
BR112016029864A2 (pt) * 2014-06-17 2017-08-22 Clearside Biomedical Inc métodos e dispositivos para tratamento de desordens oculares posteriores.
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
KR20200131839A (ko) 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
PE20211602A1 (es) 2018-12-18 2021-08-18 Novartis Ag Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf

Also Published As

Publication number Publication date
IL251696A0 (en) 2017-06-29
IL265497B (en) 2021-06-30
JP6753848B2 (ja) 2020-09-09
KR102588846B1 (ko) 2023-10-16
EP3215123A1 (en) 2017-09-13
IL251642B (en) 2021-02-28
RU2017119647A3 (es) 2019-05-29
US20160340420A1 (en) 2016-11-24
US12049495B2 (en) 2024-07-30
CL2017001115A1 (es) 2018-01-26
JP2022141923A (ja) 2022-09-29
CN107635580A (zh) 2018-01-26
AU2018278870A1 (en) 2019-01-03
RU2020114917A (ru) 2020-05-22
CN120938921A (zh) 2025-11-14
MY193913A (en) 2022-11-01
BR112017008660A2 (pt) 2017-12-26
CL2017001117A1 (es) 2018-01-26
MY183807A (en) 2021-03-16
AU2015342815A1 (en) 2017-05-11
MX2017005875A (es) 2017-06-26
MX2021006768A (es) 2021-07-15
AU2020220210B2 (en) 2022-01-20
EP3215122B1 (en) 2025-08-13
RU2020114917A3 (es) 2022-01-17
TW201625306A (zh) 2016-07-16
KR20170076781A (ko) 2017-07-04
MX383399B (es) 2025-03-13
US20200270336A1 (en) 2020-08-27
CA2966646A1 (en) 2016-05-12
JP2020079242A (ja) 2020-05-28
JP2017534638A (ja) 2017-11-24
SG11201702954XA (en) 2017-05-30
US20160130337A1 (en) 2016-05-12
JP7080263B2 (ja) 2022-06-03
EP4684797A3 (en) 2026-04-29
US20260098085A1 (en) 2026-04-09
ECSP17034829A (es) 2019-02-28
CO2017004596A2 (es) 2017-08-31
RU2017119647A (ru) 2018-12-07
US11098110B2 (en) 2021-08-24
PE20170780A1 (es) 2017-07-04
AU2020220210A1 (en) 2020-10-01
US12371481B2 (en) 2025-07-29
TWI738632B (zh) 2021-09-11
KR102724014B1 (ko) 2024-10-31
TN2017000128A1 (en) 2018-10-19
EP3215122C0 (en) 2025-08-13
CA2966758A1 (en) 2016-05-12
IL251642A0 (en) 2017-06-29
IL280087B (en) 2022-02-01
AU2018278870B2 (en) 2020-05-28
AU2018274882B2 (en) 2020-07-09
IL280087A (en) 2021-03-01
GT201700096A (es) 2019-10-10
SG10201913565RA (en) 2020-02-27
KR20170082526A (ko) 2017-07-14
TWI761959B (zh) 2022-04-21
JP2025004075A (ja) 2025-01-14
WO2016073915A1 (en) 2016-05-12
NZ730821A (en) 2019-11-29
RU2722643C2 (ru) 2020-06-02
EA201790989A1 (ru) 2017-09-29
PH12021550147A1 (en) 2023-01-23
KR20230066649A (ko) 2023-05-16
AU2018274882A1 (en) 2018-12-20
PH12017500844B1 (en) 2021-05-05
JP2017538674A (ja) 2017-12-28
AU2020244614A1 (en) 2020-11-05
EP3215122A1 (en) 2017-09-13
AU2015342818B2 (en) 2019-01-03
WO2016073918A1 (en) 2016-05-12
US10035850B2 (en) 2018-07-31
AU2020244614B2 (en) 2023-06-01
IL283561B (en) 2022-01-01
US20180298092A1 (en) 2018-10-18
MX383808B (es) 2025-03-14
US20210340242A1 (en) 2021-11-04
TW202146049A (zh) 2021-12-16
SG11201702909QA (en) 2017-05-30
US10689438B2 (en) 2020-06-23
JP2020193212A (ja) 2020-12-03
EP4684797A2 (en) 2026-01-28
PH12017500843A1 (en) 2017-10-30
TWI705827B (zh) 2020-10-01
JP6667519B2 (ja) 2020-03-18
PH12017500844A1 (en) 2017-10-30
CN106999581A (zh) 2017-08-01
CN114081951A (zh) 2022-02-25
TW202103735A (zh) 2021-02-01
ES3051145T3 (en) 2025-12-26
IL283561A (en) 2021-07-29
IL265497A (en) 2019-05-30
BR112017008093A2 (pt) 2018-03-13
TW201625221A (zh) 2016-07-16
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
TWI806150B (zh) 2023-06-21
KR20240161204A (ko) 2024-11-12

Similar Documents

Publication Publication Date Title
GT201700096A (es) Formulación estable de proteína en solución que contiene una alta concentración de un anticuerpo anti-vegf
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CL2021001587A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
CO7111300A2 (es) Formulación de anticuerpos
AR107014A1 (es) Formulación farmacéutica acuosa
CL2018003178A1 (es) Composición farmacéutica
BR112016026811A2 (pt) formulação de anticorpo
BR112015022210A2 (pt) formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica.
MX2017009759A (es) Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
AR130115A2 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf